Please login to the form below

Not currently logged in
Email:
Password:

BACE inhibitors

This page shows the latest BACE inhibitors news and features for those working in and with pharma, biotech and healthcare.

Another Alzheimer's bust as Merck & Co stops verubecestat study

Another Alzheimer's bust as Merck & Co stops verubecestat study

The failure casts a shadow on other trials of BACE inhibitors, including Biogen and Eisai’s elenbecestat (E2609), Eli Lilly’s LY3202626 and AZ-partnered lanabecestat, which are also in mid- ... That hypothesis has now taken a severe and potentially

Latest news

  • Merck BACE inhibitor adds to litany of Alzheimer's trial failures Merck BACE inhibitor adds to litany of Alzheimer's trial failures

    warning shot across the bows of companies that also have BACE inhibitors in development, includingand Novartis. ... BACE inhibitors may still have a role to play in Alzheimer's the finding "will dampen investor enthusiasm for the mechanism”.

  • Lilly sinks as solanezumab fails again in Alzheimer's Lilly sinks as solanezumab fails again in Alzheimer's

    trial in 'prodromal' patient's in the earliest stages of the disease due to report results in 2021 – as well as other pipeline projects such as its AstraZeneca-partnered BACE inhibitor ... Antibodies that directly target amyloid, small-molecule BACE

  • Surging sales of Lundbeck's CNS drugs assist recovery Surging sales of Lundbeck's CNS drugs assist recovery

    Idalopirdine (Lu AE58054) is being tested as an add-on therapy to boost the effects of cholinesterase inhibitors in Alzheimer's, so could be a less risky proposition than drugs seeking ... to tackle the underlying cause of the disease such as BACE

  • AZ-Lilly start second pivotal trial of fast-tracked Alzheimer's drug AZ-Lilly start second pivotal trial of fast-tracked Alzheimer's drug

    Given the lengthy list of failed amyloid-targeting drugs for Alzheimer's there is still a lot of risk in the development of BACE inhibitors but - for now at least - they ... AZ and Lilly are in a race to market with Eisai/Biogen, Merck &Co and

  • Eisai and Biogen plan phase III trials for Alzheimer's drug Eisai and Biogen plan phase III trials for Alzheimer's drug

    The outcome of the FDA discussions is a further boost for companies developing BACE inhibitors, which along with Eisai/Biogen also include Merck &Co, AstraZeneca/Eli Lilly and Amgen/Novartis, among ... Roche, Boehringer Ingelheim/Vitae Pharma and Lilly

More from news
Approximately 2 fully matching, plus 17 partially matching documents found.

Latest Intelligence

  • Holding on to hope for Alzheimer’s advances Holding on to hope for Alzheimer’s advances

    we need more data on the efficacy of other approaches, including beta secretase cleaving enzyme (BACE) inhibitors which may reduce amyloid formation, rather than targeting its removal like the antibody strategies.”. ... Big pharma backing BACE. A

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CACTUS

Founded in 2002, Cactus Communications is a fully integrated, global scholarly communications company with offices in Japan, South Korea, India,...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics